转移性去势抵抗性前列腺癌伴BRCA1/2基因改变患者的患者报告结局:随机3期MAGNITUDE试验最终分析
3期MAGNITUDE试验评估尼拉帕利200 mg联合阿比特龙1000 mg加泼尼松10 mg(AAP)治疗转移性去势抵抗性前列腺癌(mCRPC)伴同源重组修复(HRR)基因改变患者的疗效与安全性。本文报告HRR+队列中关注BRCA1/2改变(BRCA+)患者的患者报告结局(PRO)最终分析。BRCA+ mCRPC患者(n=225)中,尼拉帕利+AAP与安慰剂+AAP在疼痛恶化时间上无显著差异,EQ-5D-5L显示总体健康相关生活质量无临床意义差异,耐受性相似,大多数患者副作用困扰轻微。
要点
- BRCA+ mCRPC患者(n=225)中,尼拉帕利+AAP与安慰剂+AAP的BPI-SF和FACT-P疼痛恶化时间无显著差异。
- EQ-5D-5L显示治疗期间两组总体健康相关生活质量无临床意义差异。
- 副作用困扰评为「完全没有」或「有一点」的患者比例在治疗期间为79.8%至95.9%。
核心结论
- 尼拉帕利+AAP治疗维持了BRCA+ mCRPC患者的健康相关生活质量,多数患者报告的副作用困扰轻微。
- 两组间疼痛恶化时间的差异未达到常规统计学显著性水平。
研究设计与样本
- 随机3期MAGNITUDE试验(NCT03748641)的PRO最终分析,纳入BRCA+ mCRPC患者n=225。
- 使用BPI-SF、FACT-P和EQ-5D-5L问卷评估患者报告症状、健康相关生活质量和耐受性(副作用困扰)。
- 评估在指定治疗周期第1天及随访期间完成。
主要发现
- BRCA+ mCRPC患者(n=225)中,尼拉帕利+AAP与安慰剂+AAP的BPI-SF和FACT-P疼痛恶化时间无显著差异。
- 治疗期间EQ-5D-5L显示两组总体健康相关生活质量无临床意义差异。
- 耐受性两组相似,副作用困扰评为「完全没有」或「有一点」的比例在治疗期间为79.8%至95.9%。
- 在中心完成PRO评估时,平均治疗期间PRO依从性>80%。
局限性
- 样本量可能不足以检测PRO差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The phase 3 MAGNITUDE trial assessed the efficacy and safety of niraparib 200 mg and abiraterone acetate 1000 mg plus prednisone 10 mg (AAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) and alterations in homologous recombination repair (HRR) genes. Here we report final analysis results for patient-reported outcomes (PROs) in the HRR+ cohort with a focus on BRCA1/2 alterations (BRCA+). METHODS: Protocol-specified endpoints evaluated patient-reported symptoms, health-related quality of life (HRQoL), and tolerability (side-effect bother) using the Brief Pain Inventory-Short Form (BPI-SF), Functional Assessment of Cancer Therapy-Prostate (FACT-P), and EQ-5D-5L questionnaires. Evaluations were completed on day 1 of designated treatment cycles and during follow-up. KEY FINDINGS AND LIMITATIONS: All patients with BRCA+ mCRPC (n = 225) were included in the PRO analyses with average on-treatment PRO compliance >80% when completed on-site. Time to deterioration in pain according to BPI-SF and FACT-P scores did not significantly differ between niraparib + AAP and placebo + AAP. During treatment, EQ-5D-5L revealed no clinically meaningful differences in overall HRQoL between treatment arms in the BRCA+ subgroup. Finally, tolerability was similar between arms; side effect bother rated as "not at all" or "a little bit" ranged from 79.8% to 95.9% during treatment. Limitations include a sample size that may not have been powered to detect a difference in PROs. CONCLUSIONS AND CLINICAL IMPLICATIONS: Treatment with niraparib + AAP maintained HRQoL with minimal side-effect bother reported by most patients with BRCA+ mCRPC. Differences between treatment groups in time to pain deterioration did not meet conventional levels of statistical significance. The MAGNITUDE trial is registered on ClinicalTrials.gov as NCT03748641.
引用
- Rathkopf DE, Roubaud G, Chi KN, et al. Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial. Eur Urol. 2024. PMID: 39317633. doi:10.1016/j.eururo.2024.09.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。